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OBJECTIVE— High proinsulin concentration may be a better predictor for cardiovascular
disease (CVD) mortality than insulin concentration. Previous observations may have been con-
founded by glucose tolerance status or lack of precision because of high intraindividual variabil-
ity. We investigated the longitudinal relation of means of duplicate measurements of insulin and
proinsulin with all-cause and CVD mortality in a population-based cohort taking glucose toler-
ance status into account.
RESEARCH DESIGN AND METHODS— Fasting and post–75-g glucose-load (2-h)
glucose, insulin, and proinsulin values were determined in duplicate on separate days in 277
participants with normal glucose metabolism, 208 participants with impaired glucose metabo-
lism, and 119 newly detected patients with type 2 diabetes of the Hoorn Study. Insulin resistance
and -cell function were estimated by homeostasis model assessment (HOMA-IR and HOMA-B,
respectively), and the fasting proinsulin-to-insulin ratio was calculated. Subjects were followed
with respect to mortality until January 2003.
RESULTS— Fasting proinsulin levels were significantly associated with all-cause and CVD
mortality. The hazard ratios (HRs) per increase in interquartile range adjusted for age and sex were
1.21 (95% CI 1.04–1.42) for all-cause mortality and 1.33 (1.06–1.66) for CVD mortality. Adjust-
ment for glucose tolerance status and HOMA-IR did not substantially change the associations.
CONCLUSIONS— Fasting proinsulin was associated with all-cause and CVD mortality, inde-
pendent of glucose tolerance status and insulin resistance and largely independent of other CVD risk
factors. Proinsulin might play a role in the relationship between insulin resistance and CVD.
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H yperinsulinemia is a marker of in-sulin resistance and was associatedwith all-cause mortality (1) and car-
diovascular disease (CVD) mortality in
prospective studies in the general popu-
lation (2– 6). The association between
postload insulin and CVD mortality was
found to be weaker than the association
between fasting insulin and CVD mortal-
ity (2,7,8).
A number of population-based stud-
ies showed that proinsulin, the precursor
of insulin, is a better predictor of coronary
heart disease than insulin (9–12). How-
ever, in these studies, glucose tolerance
status may have confounded this relation.
Thus, less is known about the role of in-
sulin or proinsulin in the pathway to
CVD.
It has been suggested that proinsulin
as a molecule might be atherogenic (13).
In addition, higher proinsulin levels may
also be attributed to-cell dysfunction (14).
Another explanation is that insulin resis-
tance explains the relation of both insulin
and proinsulin with (CVD) mortality.
Differences in the predictive value of
insulin and proinsulin in the fasting and
the postload state are difficult to interpret
because of the inherent differences in
variability. Insulin and proinsulin con-
centrations have been shown to be highly
variable, particularly in the postload state
(15), and random misclassification leads
to an underestimation of the true associ-
ation with CVD. In the present study, in a
subsample of the population-based
Hoorn Study cohort stratified for glucose
tolerance status, fasting and postload in-
sulin and proinsulin levels were deter-
mined twice on separate days, 2 weeks
apart. Homeostasis model assessment of
insulin resistance (HOMA-IR) (16) was
used as a marker of insulin resistance. To
study the possible role of -cell dysfunc-
tion, a disproportionately elevated pro-
insulin-to-insulin ratio (17) and homeo-
stasis model assessment of -cells
(HOMA-B) (16) were calculated.
The aim of this study was, first, to
investigate the longitudinal association of
the mean of duplicate measures of fasting
and postload insulin and proinsulin con-
centrations and insulin resistance, as esti-
mated by HOMA-IR, with all-cause and
CVD mortality. The second aim was to
study the role of insulin resistance and
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glucose tolerance status in the relation be-
tween insulin or proinsulin and mortality.
All analyses were done in a population-
based cohort that was stratified for glu-
cose tolerance status.
RESEARCH DESIGN AND
METHODS— The Hoorn Study is a
population-based cohort study on type 2
diabetes in the general Dutch population.
The study population and research design
have been described in detail previously
(15). In summary, in 1989, 3,553 men
and women, aged 50–75 years, were ran-
domly selected from the population reg-
ister of the middle-sized Dutch town of
Hoorn. Of the 2,540 subjects (71.5%)
who agreed to participate, 56 non-
Caucasians were excluded. Therefore, the
study cohort consisted of 2,484 men and
women. All subjects gave written in-
formed consent. The Ethics Committee of
the VU University Medical Center ap-
proved the study. After exclusion of pa-
tients with known diabetes (n  90), as
defined by use of insulin or blood glu-
cose–lowering agents, or a prescribed diet
for diabetes, a subgroup of 1,109 partici-
pants from the initial study cohort, strat-
ified by age, sex, and 2-h postload glucose
values, was invited for a second oral glu-
cose tolerance test. For reasons of effi-
ciency, insulin and proinsulin were
measured in duplicate (2 weeks apart)
in a subsample of 630 participants of the
stratified sample of 1,109 participants, in-
cluding participants with impaired glu-
cose tolerance and all participants with
newly detected diabetes (15). Subjects
with values below the lower limit of sen-
sitivity of the insulin or proinsulin assay
were excluded. For the present analyses,
subjects were included if either insulin or
proinsulin values were available in dupli-
cate (n 605). Of these 605 subjects, one
subject was lost to follow-up. Thus, the
present study population comprised 604
subjects. A total of 602 participants had
duplicate insulin values, and proinsulin
values were available for 511 participants.
Anthropometric measurements were
obtained from all participants. Weight
was measured while participants were
wearing light clothes only. Participants
were not wearing shoes while height was
measured. BMI was calculated as weight
(in kilograms) divided by the square of
height (in meters). Waist circumference
(centimeters) was measured following a
standardized procedure (15).
Systolic and diastolic blood pressure
were determined at the right upper-arm,
after 5 min of rest in seated participants,
with a random-zero sphygmomanometer
(Hawksley-Gelman, Lancing, U.K.). The
average of duplicate measurements was
used.
All laboratory analyses were per-
formed at the VU University Medical Cen-
ter in Amsterdam. Fasting plasma glucose
concentration and 2-h postload plasma
glucose concentration were determined
by the glucose dehydrogenase method
(Merck, Darmstadt, Germany). Immuno-
specific insulin was measured in serum by
a double-antibody radio immunoassay
(lot SP21; Linco Research, St. Louis, MO)
in which proinsulin and 32,33 split pro-
insulin cross-reacts by0.2%. Proinsulin
was measured by a double-antibody ra-
dioimmunoassay (Lilly Laboratory for
Clinical Research, Indianapolis, IN) in
which 31,32 proinsulin cross-reacts by
63% (18). Triglycerides, total cholesterol,
and HDL cholesterol measured on the
first visit were determined by enzymatic
techniques (Boehringer-Mannheim,
Mannheim, Germany).
Mortality follow-up
There is a continuous follow-up to regis-
ter mortality from the participants of the
Hoorn Study, with the municipal register
of the city of Hoorn providing informa-
tion about the vital status of the partici-
pants. Information of causes of death was
obtained from medical records of general
practitioners and from the local hospital.
Causes of death were coded according to
the ICD-9 (19). CVD mortality was de-
fined as ICD-9 codes 390–459 (diseases
of the circulatory system) or 798 (sudden
death, cause unknown) because, gener-
ally, sudden death is of cardiovascular or-
igin (20). The mortality follow-up was
completed by January 2003.
Statistical methods
Glucose tolerance status (based on fasting
and postload glucose values) and fasting
and postload insulin and proinsulin val-
ues were based on the mean of two mea-
surements. If only one value was
determined, values were based on one
measurement. This was done for 1 subject
for fasting plasma glucose, 16 subjects for
postload plasma glucose, 16 subjects for
fasting insulin, and 61 subjects for fasting
proinsulin.
The mean fasting and postload glu-
cose values of duplicate oral glucose tol-
erance tests were used to define the
glucose tolerance status of the partici-
pants (21). Insulin resistance was esti-
mated by HOMA-IR, calculated as fasting
insulin (in microunits per milliliter) 
fasting glucose (in millimoles per liter)/
22.5. -Cell function was estimated by
HOMA-B, calculated as fasting insulin 
20/fasting glucose (in millimoles per liter)
 3.5 (16).
Due to skewed distributions, baseline
characteristics are shown as medians with
interquartile ranges. Differences in base-
line measurements for groups of glucose
tolerance status were examined using lin-
ear regression for continuous data and lo-
gistic regression for dichotomous data,
adjusted for age. Correlations among
insulin, proinsulin, HOMA-IR, and
HOMA-B were calculated by Spearman
correlation coefficients because of skewed
distribution of insulin and proinsulin.
Hazard ratios (HRs) and 95% CIs
were obtained from multivariate Cox pro-
portional hazards models. HRs are calcu-
lated for one increase in interquartile
range value, which is calculated for each
variable. All models were adjusted for age
and sex. We tested for possible interac-
tion between insulin, proinsulin, HOMA-
IR, and glucose tolerance status by adding
two product terms to the survival models
insulin  impaired glucose metabolism
and insulin diabetes. We also tested for
possible interaction among insulin, pro-
insulin, HOMA-IR, and sex because this
was found in some studies (2). In the sec-
ond model, we additionally adjusted for
glucose tolerance status as a potential
confounding factor. Third, we also ad-
justed for insulin resistance, calculated as
HOMA-IR, to investigate the effect of in-
sulin and proinsulin levels on (CVD)
mortality independent of HOMA-IR. To
find other potential confounding or me-
diating factors, we added fasting and
postload glucose, BMI, triglycerides, HDL
cholesterol, total cholesterol, hyperten-
sion, and current smoking one by one to
the third model. We adjusted our model
for the variables that affected the esti-
mated association. A P value 0.05 was
considered statistically significant. Test-
ing for interaction, we considered a P
value 0.10 statistically significant. Sta-
tistical analyses were performed with the
SPSS software package for Windows (ver-
sion 10.1.4).
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RESULTS— The characteristics of the
study cohort, stratified for glucose tolerance
status, are shown in Table 1. Of the 604
participants, 156 died, of whom 59 died
from CVD or sudden death during the 11
years of follow-up. There was an increasing
risk of all-cause mortality over the glucose
tolerance groups (P 0.04). For CVD mor-
tality, increase in risk over glucose tolerance
groups was not statistically significant (P
0.10). All other variables, except sex and
total cholesterol, showed statistically signif-
icant differences (P 0.05) across glucose
tolerance groups.
Spearman correlation coefficients
among insulin, proinsulin, HOMA-IR,
and HOMA-B are shown in Table 2. All
shown variables were statistically signifi-
cant and correlated with each other (P
0.01), except fasting proinsulin with
HOMA-B and proinsulin-to-insulin ratio
with postload insulin and with HOMA-
IR. Proinsulin-to-insulin ratio was statis-
tically significant but inversely related to
fasting insulin and HOMA-B.
HRs for fasting insulin, fasting proin-
sulin, and HOMA-IR, adjusted for age and
Table 1—Baseline characteristics in median values (interquartile range) and mortality in categories of glucose tolerance status (n  604)
NGM* IGM New diabetes
n 277 208 119
Baseline
Age (years) 63.8 (11.7) 64.7 (12.6) 66.2 (10.4)
Sex (% male) 48.4 48.6 47.9
BMI (kg/m2) 25.6 (4.2) 27.4 (4.7) 28.1 (5.1)
Waist circumference (cm) 89.5 (13.2) 95.0 (15.0) 99.5 (15.8)
Fasting glucose (mmol/l)† 5.30 (0.55) 6.05 (0.79) 7.40 (1.75)
2-h postload glucose (mmol/l)† 5.75 (2.23) 8.50 (1.54) 12.65 (4.95)
Triglycerides (mmol/l) 1.30 (0.80) 1.70 (1.10) 2.00 (1.50)
HDL cholesterol (mmol/l) 1.35 (0.49) 1.17 (0.47) 1.10 (0.36)
Total cholesterol (mmol/l) 6.60 (1.50) 6.80 (1.50) 6.50 (1.70)
Diastolic blood pressure (mmHg)† 80.0 (13.0) 83.0 (11.5) 84.3 (11.5)
Systolic blood pressure (mmHg)† 130.5 (22.0) 140 (27.4) 144 (20.8)
Hypertension (%)‡ 27.5 48.6 55.5
Current smoker (%) 31.4 21.6 21.0
Fasting-specific insulin (pmol/l)† 72.1 (36.8) 88.6 (53.9) 117.2 (70.4)
Fasting proinsulin (pmol/l)† 9.5 (7.9) 14.2 (12.9) 21.7 (20.0)
Proinsulin-to-insulin ratio† 0.12 (0.11) 0.14 (0.13) 0.16 (0.14)
Postload-specific insulin (pmol/l)† 310.5 (260.4) 532.6 (542.7) 600.5 (567.3)
Postload proinsulin (pmol/l)† 49.8 (49.2) 74.9 (63.4) 93.4 (67.2)
HOMA-IR 2.80 (1.55) 4.01 (2.47) 6.61 (4.53)
HOMA-B 137.4 (75.5) 123.2 (85.8) 104.4 (81.3)
11-year follow-up
All-cause death [n (%)] 59 (21.3) 55 (26.4) 42 (35.3)
CVD mortality or sudden death n (%) 20 (7.2) 22 (10.6) 17 (14.3)
Values within parentheses represent interquartile ranges unless otherwise indicated. Linear regression for continuous variables: P0.05, except for total cholesterol
(P 0.98). Logistic regression for percentages: P0.05, except for sex (P 0.69) and CVD mortality (P 0.10). *Glucose tolerance status based on the mean fasting
and 2-h postload glucose levels of two oral glucose tolerance tests; †based on the mean of two measurements; ‡hypertension (diastolic blood pressure95 mmHg
or systolic blood pressure 160 mmHg or medication). NGM, normal glucose metabolism (fasting glucose 6.1 mmol/l and 2-h glucose 7.8 mmol/l); IGM,
impaired glucose metabolism (fasting glucose6.1 and7.0 mmol/l or 2-h glucose7.8 and11.1 mmol/l); diabetes, fasting glucose7.0 mmol/l or 2-h glucose
11.1 mmol/l; HOMA-IR, fasting insulin (in microunits per milliliter) fasting glucose (in millimoles per liter)/22.5; HOMA-B, fasting insulin (in microunits per
milliliter)  20/fasting glucose (in millimoles per liter)  3.5.
Table 2—Spearman correlation coefficients for insulin and proinsulin, HOMA-IR, and HOMA-B
Fasting-
specific insulin
Fasting
proinsulin
Proinsulin-to-
insulin ratio
Postload-
specific insulin
Postload
proinsulin HOMA-IR
Fasting proinsulin 0.47*
Proinsulin-to-insulin ratio 0.14* 0.78*
Postload-specific insulin 0.67* 0.43* 0.04
Postload proinsulin 0.51* 0.68* 0.41* 0.74*
HOMA-IR 0.95* 0.53* 0.04 0.63* 0.52*
HOMA-B 0.63* 0.09 0.34* 0.44* 0.25* 0.38*
*Correlation is statistically significant (P 0.01). HOMA-IR, fasting insulin (in microunits per milliliter) fasting glucose (in millimoles per liter)/22.5; HOMA-B,
fasting insulin (in microunits per milliliter)  20/fasting glucose (in millimoles per liter)  3.5.
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sex, were calculated for separate strata of
glucose tolerance. The HRs for insulin
and HOMA-IR were the highest in the
normal glucose metabolism group (data
not shown). Proinsulin was associated
with mortality in all groups of glucose tol-
erance status. Since the tests for interac-
tions among insulin, proinsulin, HOMA-
IR, and glucose tolerance status were not
statistically significant (P 	0.10), these
groups were combined for subsequent
analyses.
In Table 3, HRs per increase in inter-
quartile range, calculated from the
present study population for both all-
cause and CVD mortality, are shown.
Fasting insulin, proinsulin-to-insulin ra-
tio, postload insulin and proinsulin lev-
els, and HOMA-B were not significantly
associated with all-cause or CVD mortal-
ity. Fasting proinsulin, however, was sig-
nificantly associated with all-cause
mortality (HR 1.21 [95% CI 1.04–1.42])
and CVD mortality (1.33 [1.06–1.66]),
adjusting for age and sex. After adjust-
ment for glucose tolerance status and ad-
ditionally for HOMA-IR, the HRs for
proinsulin were only slightly attenuated
and remained significant. HOMA-IR was
associated with all-cause mortality (1.16
[1.01–1.32]) but not with CVD mortality.
By including fasting proinsulin in the
model of HOMA-IR, the association be-
tween HOMA-IR and all-cause mortality
disappeared (1.00 [0.83–1.20]). Also, by
including proinsulin in the model of in-
sulin, HRs for insulin became smaller (Ta-
ble 3), whereas HRs for proinsulin did not
substantially change (data not shown).
In addition, we tested for other poten-
tial confounding risk factors (Table 3) in
the relation between proinsulin and
(CVD) mortality. Only triglycerides and
hypertension slightly attenuated the asso-
ciation between proinsulin and all-cause
mortality. Other risk factors, i.e., fasting
and postload glucose, BMI, HDL choles-
terol, total cholesterol, and HOMA-B, did
not change the association between pro-
insulin and mortality (data not shown).
The associations with mortality did not
differ between men and women (data not
shown).
CONCLUSIONS— In the present
study, in a subsample of a population-
based prospective study, we found that
proinsulin was an independent risk factor
for both all-cause and CVD mortality, also
after adjusting for both insulin resistance
and glucose tolerance status.
Fasting proinsulin per increase in in-
terquartile range was associated with a
21% higher all-cause mortality and a 33%
higher CVD mortality. The association of
proinsulin with mortality risk appeared
stronger than that of insulin with mortal-
ity risk. This has also been observed in
another longitudinal study (9) and in
cross-sectional studies (22,23). More-
over, in a model that included both pro-
insulin and insulin or HOMA-IR,
proinsulin remained significantly associ-
ated with (CVD) mortality, whereas insu-
l in or HOMA-IR did not remain
statistically significant. Only one previous
study considered insulin as a covariate
(11). In that study, proinsulin remained
an independent risk factor for stroke, and
the excess risk of insulin disappeared
when proinsulin was added to the model.
High proinsulin levels can be a result
of insulin resistance or -cell failure, and
both may contribute to the association be-
tween proinsulin and CVD. Proinsulin
has been shown to be strongly associated
Table 3—Hazard ratios for fasting and postload insulin and proinsulin, HOMA-IR, and
HOMA-B (n  604)
IR value
HR per increase
in IR (95% CI)
for all-cause
mortality
HR per increase
in IR (95% CI)
for CVD
mortality
Fasting-specific insulin 51.6 pmol/l
Model 1 1.15 (0.98–1.35) 1.14 (0.87–1.49)
Model 2 1.09 (0.91–1.31) 1.04 (0.77–1.40)
Model 3 1.00 (0.71–1.41) 0.92 (0.53–1.60)
Model 1 
 proinsulin 1.00 (0.81–1.22) 0.90 (0.65–1.25)
Fasting proinsulin 12.8 pmol/l
Model 1 1.21 (1.04–1.42) 1.33 (1.06–1.66)
Model 2 1.19 (1.00–1.40) 1.27 (1.00–1.63)
Model 3 1.21 (1.00–1.46) 1.34 (1.01–1.76)
Model 3 
 triglycerides 1.18 (0.97–1.43) 1.29 (0.97–1.72)
Model 3 
 hypertension* 1.19 (0.98–1.44) 1.31 (0.99–1.73)
Model 3 
 current smoking 1.23 (1.01–1.49) 1.37 (1.03–1.81)
Proinsulin-to-insulin ratio 0.12
Model 1 1.11 (0.96–1.28) 1.19 (0.97–1.47)
Model 2 1.10 (0.95–1.28) 1.17 (0.95–1.45)
Model 3 1.11 (0.95–1.29) 1.18 (0.95–1.47)
Postload-specific insulin 408 pmol/l
Model 1 1.06 (0.95–1.19) 1.10 (0.93–1.31)
Model 2 1.03 (0.91–1.17) 1.06 (0.87–1.28)
Model 3 1.01 (0.88–1.16) 1.04 (0.85–1.28)
Postload proinsulin 57.5 pmol/l
Model 1 1.12 (0.92–1.37) 1.26 (0.93–1.70)
Model 2 1.07 (0.87–1.33) 1.16 (0.84–1.61)
Model 3 1.06 (0.85–1.31) 1.15 (0.82–1.60)
HOMA-IR 2.82
Model 1 1.16 (1.01–1.32) 1.16 (0.94–1.44)
Model 2 1.10 (0.93–1.30) 1.07 (0.82–1.40)
Model 3 — —
Model 1 
 proinsulin 1.00 (0.83–1.20) 0.97 (0.73–1.29)
HOMA-B 82.3
Model 1 0.99 (0.83–1.19) 0.94 (0.69–1.28)
Model 2 1.03 (0.86–1.24) 0.99 (0.73–1.35)
Model 3 0.99 (0.81–1.21) 0.95 (0.68–1.34)
HOMA-IR, fasting insulin (in microunits per milliliter)  fasting glucose (in millimoles per liter)/22.5;
HOMA-B, fasting insulin (in microunits per milliliter)  20/fasting glucose (in millimoles per liter)  3.5.
*Hypertension: Diastolic blood pressure95 mmHg or systolic blood pressure160 mmHg or medication.
Model 1: Adjusted for age and sex. Model 2: Adjusted for age, sex, and glucose tolerance status. Model 3:
Adjusted for age, sex, glucose tolerance status, and HOMA-IR. IR, interquartile range.
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with insulin resistance in a recent study
(24), which may at least partly explain the
association with CVD and mortality
(25,26). A strong correlation between
proinsulinandHOMA-IRcancausemulti-
collinearity when both variables are in-
cluded in the same model. In the present
study, the Spearman correlation coeffi-
cient between proinsulin and HOMA-IR
was 0.53, substantially lower than the
0.90 cutoff value, which is often used as a
rule of thumb to define multicollinearity.
We found that the association between
proinsulin and (CVD) mortality was inde-
pendent of insulin resistance. In contrast,
the association between HOMA-IR and
CVD mortality disappeared following ad-
justment for proinsulin. Therefore, high
proinsulin levels might be an intermedi-
ate factor in the association between insu-
lin resistance and CVD risk, in which high
proinsulin levels are more closely related
to CVD than insulin resistance.
High proinsulin levels may also be at-
tributed to -cell dysfunction or an in-
creased demand on the -cells (14). In
the current study, disproportionately ele-
vated proinsulin-to-insulin ratios or
HOMA-B (16) were not associated with
an increased risk of CVD mortality, sug-
gesting that proinsulin per se may
contribute to the atherogenic or thrombo-
genic process. Indeed, a clinical study in
which human proinsulin was adminis-
tered for at least 1 year was stopped when
six patients treated with human proinsu-
lin had adverse cardiovascular events
(13), whereas subjects treated with insu-
lin had no adverse events.
In the IRAS (Insulin Resistance Ath-
erosclerosis Study), plasminogen activa-
tor inhibitor-1 (PAI-1) was suggested to
play a role in the association between pro-
insulin and CVD (22). Increased PAI-1
activity promotes both fibrosis and
thrombosis and is associated with CVD
(27). It was already shown that PAI-1 ac-
tivity increased after insulin or proinsulin
was administered in vitro (28) and in vivo
(29). Unfortunately, in the Hoorn Study,
data on PAI-1 are not available. PAI-1 lev-
els are elevated in subjects with insulin
resistance, impaired glucose metabolism,
and the metabolic syndrome (27). There-
fore, the metabolic syndrome, which is
defined by high triglycerides, impaired
glucose metabolism, hypertension, ab-
dominal obesity, and/or low HDL (30), is
another potential confounding factor in
the relation between proinsulin and CVD
risk. However, in our data, triglyceride
concentration, glucose tolerance status,
and hypertension explained only a small
part of the association between proinsulin
and CVD risk.
Hyperinsulinemia has been shown to
predict all-cause (1) and CVD mortality
(2,4,5,8) in the general population. We
did find an association between insulin
and CVD mortality, similar to the findings
in the meta-analysis of the DECODE (Di-
abetes Epidemiology: Collaborative Anal-
ysis of Diagnostic Criteria in Europe)
Insulin Study Group. However, in the
present study, the association between in-
sulin and CVD mortality was not signifi-
cant, probably because of the relatively
small number of case subjects.
In a number of studies, the associa-
tion between insulin and coronary heart
disease was J-shaped (3) or U-shaped
(31). In the present subpopulation of the
Hoorn Study, the number of cases was too
small to explore this association. When
we analyzed the entire Hoorn Study pop-
ulation, baseline insulin levels were avail-
able for 1,806 participants with normal
glucose metabolism. Indeed, the HRs for
fasting-specific insulin of the lowest quin-
tile against the middle three quintiles, ad-
justed for age and sex, were 1.10 (95% CI
0.81–1.50) for all-cause mortality and
1.07 (0.65–1.75) for CVD mortality (un-
published data). For the present analysis,
we did not consider this a relevant devia-
tion of a linear association.
In some studies, postload insulin lev-
els, 2 h after a 75-g glucose load, have
been associated with coronary artery dis-
ease (7,8). In the present study, postload
insulin levels were not significantly asso-
ciated with mortality, and the association
was weaker than between fasting insulin
and mortality. These results are consistent
with findings from a recent meta-analysis
(2). The weaker association between post-
load insulin and mortality was explained
by the larger biological variation of post-
load insulin levels. In our study, biologi-
cal variation was reduced by measuring
insulin levels in duplicate, but this could
still play a role in attenuating the associa-
tion between postload insulin and mortal-
ity.
We did not use gold standard tech-
niques for measuring insulin sensitivity
(i.e., the hyperinsulinemic-euglycemic
clamp) and for -cell function (i.e., the
hyperglycemic clamp) (32). Instead,
HOMA-IR was used as an estimate of in-
sulin resistance (16). In previous studies,
HOMA-IR was found to be a predictor of
CVD in diabetic patients (25,33). How-
ever, HOMA-IR cannot be used to esti-
mate insulin resistance in diabetic
patients (34). Therefore, patients with
known diabetes were excluded from the
present study. Our observation that insu-
lin levels and HOMA-IR were the stron-
gest predictors of all-cause and CVD
mortality in subjects with a normal glu-
cose tolerance status might be explained
by the fact that insulin and HOMA-IR are
less accurate indexes of insulin resistance
in patients with impaired glucose metab-
olism or newly detected type 2 diabetes.
A strength of our study is that levels of
insulin, proinsulin, and glucose were
measured twice to improve the precision.
We included participants with newly di-
agnosed diabetes and with impaired glu-
cose metabolism to enlarge the range of
distribution of insulin, proinsulin,
HOMA-IR, and HOMA-B. Also, these
subjects are especially important to in-
clude because of their enhanced CVD
risk.
In our study, proinsulin concentra-
tion was associated with both all-cause
and CVD mortality, independent of glu-
cose tolerance status and insulin resis-
tance. In addition, we showed that the
association between HOMA-IR and all-
cause mortality disappeared when proin-
sulin was entered into the model. High
proinsulin levels might therefore play a
role in the atherothrombotic process, pos-
sibly as an intermediate in the association
between insulin resistance and CVD risk.
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